XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Tables)
 3 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Assets acquired and liabilities assumed

The Pediatric Portfolio

 

   As of
   November 1, 2019
Consideration   
Cash and cash equivalents  $4,500,000 
Fair value of Series G Convertible Preferred Stock     
Total shares issued   9,805,845 
Estimated fair value per share of Aytu common stock  $0.567 
Estimated fair value of equity consideration transferred   5,559,914 
Total consideration transferred  $10,059,914 
Recognized amounts of identifiable assets acquired and liabilities assumed     
Inventory, net  $459,123 
Prepaid assets   1,743,555 
Other current assets   2,525,886 
Intangible assets - product marketing rights   22,700,000 
Accrued liabilities   (300,000)
Accrued product program liabilities   (6,683,932)
Assumed fixed payment obligations  $(29,837,853)
Total identifiable net assets   (9,393,221)
Goodwill  $19,453,135 

 

Innovus Merger (Consumer Health Portfolio)

 

   As of
   February 14, 2020
Consideration   
Fair Value of Aytu Common Stock     
Total shares issued at close   3,810,393 
Estimated fair value per share of Aytu common stock  $0.756 
Estimated fair value of equity consideration transferred  $2,880,581 
Fair value of Seris H Convertile Preferred Stock     
Total shares issued   1,997,736 
Estimated fair value per share of Aytu common stock  $0.756 
Estimated fair value of equity consideration transferred  $1,510,288 
Fair value of former Innovus warrants  $15,315 
Fair value of Contingent Value Rights  $7,049,079 
Forgiveness of Note Payable owed to the Company  $1,350,000 
Total consideration transferred  $12,805,263 

 

   As of
   February 14, 2020
Total consideration transferred  $12,805,263 
Recognized amounts of identifiable assets acquired and liabilities assumed     
Cash and cash equivalents  $390,916 
Accounts receivable, net   278,826 
Inventory, net   1,149,625 
Prepaid expenses and other current assets   1,692,133 
Other long-term assets   36,781 
Right-to-use assets   328,410 
Property, plant and equipment   190,393 
Trademarks and patents   11,744,000 
Accounts payable and accrued other expenses   (7,202,309)
Other current liabilities   (629,601)
Notes payable   (3,056,361)
Lease liability   (754,822)
Total identifiable assets  $4,167,991 
Goodwill  $8,637,272 

 
Pro forma information
    September 30, 2019 
    Pro forma 
    Unaudited 
Total revenues, net   $ 10,606,870  
Net (loss)     (8,256,982 )
Net (loss) per share (aa)   $ (0.29 )

 

(aa) Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.